Research programme: LpxC inhibitors - Forge Therapeutics
Alternative Names: FG-944; FG-LpxC; FG-LpxC LUNG; FG-LpxC UTILatest Information Update: 29 Aug 2024
At a glance
- Originator Forge Therapeutics
- Class Anti-infectives; Antibacterials; Small molecules
- Mechanism of Action LpxC inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-negative infections; Respiratory tract infections; Urinary tract infections
- Research Sexually transmitted infections
Most Recent Events
- 29 Aug 2024 Preclinical development for urinary tract infections is ongoing the US (Blacksmith Medicines pipeline, August 2024)
- 19 Mar 2024 Blacksmith Medicines files for patent protection for LpxC inhibitor in USA
- 19 Mar 2024 Preclinical development for Gram-negative infections in USA (unspecified route) before March 2024